Skip to main content
. 2022 Aug 9;14(8):1657. doi: 10.3390/pharmaceutics14081657

Figure 4.

Figure 4

CorA plasma concentration time profiles in BALB/c mice: (A) IV administration of a CorA-solution (36 mg/kg) (Data from Ref. [14]); (B) PO administration of neat CorA (■), CorA-povidone () and CorA-copovidone () (36 mg/kg), administered as an aqueous suspension in female BALB/c mice (median ± IQR, n = 4 per group).